ERCC2/XPD gene polymorphisms and lung cancer: A HuGE review

American Journal of Epidemiology

Volumn 161, Issue 1, 2005, Pages 1-14

  Benhamou, Simone ^a,b   Sarasin, Alain ^b  

^a UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Epidemiology; ERCC 2 protein; ERCC2 XPD; Genetics; Lung neoplasms; Polymorphism (genetics); Xeroderma pigmentosum

Indexed keywords

ASPARAGINE; ASPARTIC ACID; GLUTAMINE; HELICASE; LYSINE; PROTEIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

CANCER;

ALLELE; AMINO ACID SUBSTITUTION; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; CLINICAL TRIAL; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; ERCC2 GENE; EXCISION REPAIR; EXON; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG CANCER; MEDICAL LITERATURE; META ANALYSIS; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; XPD GENE;

DNA HELICASES; DNA-BINDING PROTEINS; EXONS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; TRANSCRIPTION FACTORS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 11144245523     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi018     Document Type: Review

References (61)

1. Weber CA, Salazar EP, Stewart SA, et al. ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. EMBO J 1990;9:1437-47.
2. Schaeffer L, Moncollin V, Roy R, et al. The ERCC2/DNA repair protein is associated with the class II BTF2/THIIH transcription factor. EMBO J 1994;13:2388-92.
3. Tirode F, Busso D, Coin F, et al. Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Mol Cell 1999;3: 87-95.
4. Friedberg EC. DNA damage and repair. Nature 2003;421:436-40.
5. Stary A, Sarasin A. The genetics of the hereditary xeroderma pigmentosum syndrome. Biochimie 2002;84:49-60.
6. Broughton BC, Steingrimsdottir H, Lehmann AR. Five polymorphisms in the coding sequence of the xeroderma pigmentosum group D gene. Mutat Res 1996;362:209-11.
7. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58: 604-8.
8. Mohrenweiser HW, Xi T, Vazquez-Matias J, et al. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 2002;11:1054-64.
9. Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000;21:965-71.
10. Palli D, Russo A, Masala G, et al. DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample. Int J Cancer 2001;94:121-7.
11. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
12. Hou SM, Falt S, Angelini S, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002;23:599-603.
13. Qiao Y, Spitz MR, Guo Z, et al. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 2002;509:165-74.
14. Tang D, Cho S, Rundle A, et al. Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treat 2002;75:159-66.
15. Matullo G, Peluso M, Polidoro S, et al. Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol Biomarkers Prev 2003;12:674-7.
16. Winsey SL, Haldar NA, Marsh HP, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000;60:5612-16.
17. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 2000;21:2219-23.
18. Vogel U, Hedayati M, Dybdahl M, et al. Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis 2001;22:899-904.
19. Caggana M, Kilgallen J, Conroy JM, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 2001;10:355-60.
20. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002; 23:295-9.
21. Liang G, Xing D, Miao X, et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003;105:669-73.
22. Misra RR, Ratnasinghe D, Tangrea JA, et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 2003;191:171-8.
23. Zhou W, Liu G, Miller DP, et al. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res 2002;62:1377-81.
24. Sturgis EM, Dahlstrom KR, Spitz MR, et al. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002;128:1084-8.
25. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 2002;23:1321-5.
26. Park JY, Lee SY, Jeon HS, et al. Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. (Letter). Lung Cancer 2002;36:15-16.
27. Hamajima N, Saito T, Matsuo K, et al. Genotype frequencies of 50 polymorphisms for 241 Japanese non-cancer patients. J Epidemiol 2002;12:229-36.
28. Shen M, Hung RJ, Brennan P, et al. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in Northern Italy. Cancer Epidemiol Biomarkers Prev 2003;12:1234-40.
29. David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:911-12.
30. Stern MC, Johnson LR, Bell DA, et al. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1004-11.
31. International Agency for Research on Cancer. Lung cancer. In: Stewart BW, Kleihues P, eds. World cancer report. Lyon, France: International Agency for Research on Cancer, 2003: 182-7.
32. Parkin DM, Whelam SL, Ferlay J, et al. Cancer incidence in five continents. Vol 8. (IARC Scientific Publication no. 155). Lyon, France: International Agency for Research on Cancer, 2002.
33. Blot WJ, Fraumeni JF. Cancers in the lung and pleura. In: Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention. New York, NY: Oxford University Press, 1996: 637-65.
34. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst 1984;73:383-9.
35. International Agency for Research on Cancer. Tobacco smoking and involuntary tobacco smoke. (IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol 83). Lyon, France: International Agency for Research on Cancer, 2004.
36. Boffetta P. Involuntary smoking and lung cancer. Scand J Work Environ Health 2002;28:30-40.
37. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315:980-8.
38. Brennan PJ, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 2004;109:125-31.
39. International Agency for Research on Cancer. Fruit and vegetables. (IARC Handbooks of Cancer Prevention, vol 8). Lyon, France: International Agency for Research on Cancer, 2003.
40. Vineis P, Veglia F, Benhamou S, et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Im J Cancer 2003;104:650-7.
41. Taioli E, Gaspari L, Benhamou S, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003;32:60-3.
42. Le Marchand L, Guo C, Benhamou S, et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 2003;14:339-46.
43. Hung RJ, Boffetta P, Brockmoller J, et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003;24:875-82.
44. Benhamou S, Lee WJ, Alexandrie A-K, et al. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphism and smoking on lung cancer risk. Carcinogenesis 2002;23:1343-50.
45. Stucker I, Hirvonen A, de Waziers I, et al. Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility. Carcinogenesis 2002;23:1475-81.
46. Feyler A, Voho A, Bouchardy C, et al. Myeloperoxidase -463 G→A polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1550-4.
47. Lee WJ, Brennan P, Boffetta P, et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002;7:230-41.
48. Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001;22:593-7.
49. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
50. Greenland S. Meta-analysis. In: Rothman KJ, Greenland S, eds. Modern epidemiology. Philadelphia, PA: Lippincott-Raven, 1998:643-73.
51. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
52. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:359-65.
53. Pastorelli R, Cerri A, Mezzetti M, et al. Effect of DNA repair gene polymorphisms on BPDE-DNA adducts in human lymphocytes. Int J Cancer 2002;100:9-13.
54. Sarasin A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat Res 2003;544:99-106.
55. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
56. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
57. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002;23:381-7.
58. Caporaso NE. Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev 2002;11:1544-9.
59. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
60. Tregouet DA, Barbaux S, Escolano S, et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet 2002;11:2015-23.
61. Zhao LP, Li SS, Khalid N. A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 2003;72:1231-50.